StratDeck

Two stocks in Healthcare

Hikma Pharmaceuticals vs Oxford Biomedica: profit, growth, debt and price compared

Hikma Pharmaceuticals is stronger on 5 of 6 figures: profit margin, debt, price for its expected profit, analysts' view and price trend. Oxford Biomedica is stronger on 1: sales growth.

Figures as of 18 November 2026Yahoo Finance
Explore Hikma Pharmaceuticals' storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

Hikma Pharmaceuticals and Oxford Biomedica side by side
Hikma PharmaceuticalsHIK.LOxford BiomedicaOXB.L
Net marginStronger: 11.3%−23.2%
Revenue growth, past year+4.20%Stronger: +9.00%
Debt to equityStronger: 77.1%273.1%
Forward P/EStronger: 9.2×Loss
Dividend yield3.84%—
AnalystsStronger: Strong buy · 12Buy · 8
From its 200-day averageStronger: +5.8%−5.2%

Share price over the past year

  • Hikma Pharmaceuticals+7.7%
  • Oxford Biomedica−13.2%

20 Nov 202518 Nov 2026

Hikma Pharmaceuticals or Oxford Biomedica: which is stronger?

  • HIK.L

    Which is more profitable?

    Hikma Pharmaceuticals keeps more of each sale as profit: 11.3% against −23.2%.

  • OXB.L

    Which is growing its sales faster?

    Oxford Biomedica is growing its sales faster: +9.00% over the past year, against +4.20%.

  • HIK.L

    Which has borrowed less?

    Hikma Pharmaceuticals has borrowed less: its debt is 77.1% of what its shareholders own, against 273.1% for Oxford Biomedica.

  • HIK.L

    Which costs less for the profit it is expected to make?

    Hikma Pharmaceuticals is expected to make a profit over the next year, where Oxford Biomedica is expected to make a loss.

  • Which pays more in dividends?

    Hikma Pharmaceuticals pays 3.84% a year in dividends for what a share costs, where Oxford Biomedica pays none.

  • HIK.L

    Which do analysts rate higher?

    Analysts are warmer on Hikma Pharmaceuticals: Strong buy, against Buy for Oxford Biomedica.

  • HIK.L

    Which is in the stronger price trend?

    Hikma Pharmaceuticals' price is in the stronger trend: 5.8% above its 200-day average, against 5.2% below.

What each company does

HIK.LHikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products.

Reports results on 25 February 2027

OXB.LOxford Biomedica

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.

Reports results on 25 March 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every UK healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.